Ildiko Mesteri1, Sebastian F Schoppmann2, Matthias Preusser3, Peter Birner4. 1. Department of Pathology, Medical University of Vienna, A-1090 Vienna, Austria; Comprehensive Cancer Center Vienna Gastroesophageal Cancers Unit (CCC-GET), Medical University of Vienna, A-1090 Vienna, Austria. 2. Comprehensive Cancer Center Vienna Gastroesophageal Cancers Unit (CCC-GET), Medical University of Vienna, A-1090 Vienna, Austria; Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria. 3. Comprehensive Cancer Center Vienna Gastroesophageal Cancers Unit (CCC-GET), Medical University of Vienna, A-1090 Vienna, Austria; Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, A-1090 Vienna, Austria. 4. Department of Pathology, Medical University of Vienna, A-1090 Vienna, Austria; Comprehensive Cancer Center Vienna Gastroesophageal Cancers Unit (CCC-GET), Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: peter.birner@meduniwien.ac.at.
Abstract
BACKGROUND: Inhibition of cMet is a promising therapeutic approach in human cancer, but few data in oesophageal cancer exist. METHODS: Expression of mesenchymal-epithelial transition factor (cMet), epidermal growth factor receptor (EGFR) and phosphatase and tensin homologue (PTEN) were investigated immunohistochemically in 246 oesophageal carcinomas (128 adenocarcinomas (AC); 118 squamous cell carcinomas (SCC)) and corresponding metastases in a subset of AC (n=42). Data on phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and HER2 expression and on lymphovascular invasion (LVI) of tumour cells were available from previous studies. RESULTS: Overexpression of cMet was seen in 44 (34.4%) of AC, and nine (7.6%) of SCC (p<0.001, Chi square test). In AC but not in SCC, cMet expression correlated with EGFR expression (p<0.001, Chi square test), pSTAT3 expression (p=0.01, Chi square tests) and LVI of tumour cells (p<0.001, Chi square test). Overexpression of cMet was associated with shorter disease free, disease specific and overall survival of AC patients (p<0.05, Cox regression, respectively). All cMet positive ACs in which metastases were investigated had also cMet positive lymph node and distant metastases, but 25% of cMet negative primary tumours showed cMet positive lymph node and 33% distant metastases. CONCLUSIONS: CMet plays no relevant role in most oesophageal SCC. In contrast, cMet overexpression seems to be a key oncogene in about 35% of oesophageal AC, representing a highly promising therapeutic target and prognostic factor.
BACKGROUND: Inhibition of cMet is a promising therapeutic approach in human cancer, but few data in oesophageal cancer exist. METHODS: Expression of mesenchymal-epithelial transition factor (cMet), epidermal growth factor receptor (EGFR) and phosphatase and tensin homologue (PTEN) were investigated immunohistochemically in 246 oesophageal carcinomas (128 adenocarcinomas (AC); 118 squamous cell carcinomas (SCC)) and corresponding metastases in a subset of AC (n=42). Data on phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and HER2 expression and on lymphovascular invasion (LVI) of tumour cells were available from previous studies. RESULTS: Overexpression of cMet was seen in 44 (34.4%) of AC, and nine (7.6%) of SCC (p<0.001, Chi square test). In AC but not in SCC, cMet expression correlated with EGFR expression (p<0.001, Chi square test), pSTAT3 expression (p=0.01, Chi square tests) and LVI of tumour cells (p<0.001, Chi square test). Overexpression of cMet was associated with shorter disease free, disease specific and overall survival of AC patients (p<0.05, Cox regression, respectively). All cMet positive ACs in which metastases were investigated had also cMet positive lymph node and distant metastases, but 25% of cMet negative primary tumours showed cMet positive lymph node and 33% distant metastases. CONCLUSIONS:CMet plays no relevant role in most oesophageal SCC. In contrast, cMet overexpression seems to be a key oncogene in about 35% of oesophageal AC, representing a highly promising therapeutic target and prognostic factor.
Authors: Sinéad A Noonan; Lynne Berry; Xian Lu; Dexiang Gao; Anna E Barón; Patrick Chesnut; Jamie Sheren; Dara L Aisner; Dan Merrick; Robert C Doebele; Marileila Varella-Garcia; D Ross Camidge Journal: J Thorac Oncol Date: 2016-06-01 Impact factor: 15.609
Authors: Brett L Ecker; Laura Taylor; Paul J Zhang; Emma E Furth; Gregory G Ginsberg; Matthew T McMillan; Jashodeep Datta; Brian J Czerniecki; Robert E Roses Journal: PLoS One Date: 2016-08-25 Impact factor: 3.240
Authors: Florian T Unger; Nicole Lange; Jana Krüger; Carolyn Compton; Helen Moore; Lokesh Agrawal; Hartmut Juhl; Kerstin A David Journal: J Transl Med Date: 2016-01-08 Impact factor: 5.531